Treatment response after 6 courses (or at switch during the 6 courses) according to randomization and baseline stage B or C
| . | ChOP3-150(%) . | CAP3-151 (%) . | FAMP3-152 (%) . |
|---|---|---|---|
| All patients | |||
| Clinical remission | 104 (29.6) | 36 (15.2) | 135 (40.1) |
| Partial remission | 147 (41.9) | 102 (43.0) | 104 (31.0) |
| Failure3-153 | 100 (28.5) | 99 (41.8) | 97 (28.9) |
| Baseline stage B | |||
| Clinical remission | 70 (29.4) | 28 (16.1) | 96 (41.2) |
| Partial remission | 114 (47.9) | 80 (46.0) | 81 (34.8) |
| Failure3-153 | 54 (22.7) | 66 (37.9) | 56 (24.0) |
| Baseline stage C | |||
| Clinical remission | 34 (30.1) | 8 (12.7) | 39 (37.9) |
| Partial remission | 33 (29.2) | 22 (34.9) | 23 (22.3) |
| Failure3-153 | 46 (40.7) | 33 (52.4) | 41 (39.8) |
| . | ChOP3-150(%) . | CAP3-151 (%) . | FAMP3-152 (%) . |
|---|---|---|---|
| All patients | |||
| Clinical remission | 104 (29.6) | 36 (15.2) | 135 (40.1) |
| Partial remission | 147 (41.9) | 102 (43.0) | 104 (31.0) |
| Failure3-153 | 100 (28.5) | 99 (41.8) | 97 (28.9) |
| Baseline stage B | |||
| Clinical remission | 70 (29.4) | 28 (16.1) | 96 (41.2) |
| Partial remission | 114 (47.9) | 80 (46.0) | 81 (34.8) |
| Failure3-153 | 54 (22.7) | 66 (37.9) | 56 (24.0) |
| Baseline stage C | |||
| Clinical remission | 34 (30.1) | 8 (12.7) | 39 (37.9) |
| Partial remission | 33 (29.2) | 22 (34.9) | 23 (22.3) |
| Failure3-153 | 46 (40.7) | 33 (52.4) | 41 (39.8) |
Response was not available in some patients due to loss to follow-up or nonevaluation of response in some untreated patients.
Randomized, n = 357; evaluable, n = 351.
Randomized, n = 240; evaluable, n = 237.
Randomized, n = 341; evaluable, n = 336.
Stabilization, progression, or early death.